Siegfried has inked a deal to acquire Curia Global’s early-phase manufacturing site in Grafton, Wisconsin, in a move that expands the Swiss CDMO’s reach in the U.S. and its ability to offer a wider range of services.
The sale comes a little more than two months after Siegfried’s chief executive was poached by rival Lonza.
Although financial details of the facility purchase from Curia weren’t disclosed, the sale is expected to wrap up by July 1 and is being financed from existing company funds, Siegfried said in a June 12 press release.
The Wisconsin facility specializes in early-phase development and manufacturing services and employs more than 80 workers. Siegfried said it plans to develop the site into a hub for early-phase CDMO services for its global customers, which will include services for projects with highly potent drug ingredients.
“With this acquisition, we enhance our offering with early-stage development services for drug substances and become even more relevant and attractive to our customers,” Reto Suter, Siegfried’s interim CEO and CFO, said in the release. “This transaction will generate attractive opportunities and will further accelerate our growth story.”
Suter is filling in as chief executive after the news broke in early April that 14-year Siegfried veteran Wolfgang Wienand was leaving to take the helm at Swiss compatriot Lonza. Wienand’s role at Lonza is expected to begin this summer.
Lonza experienced several years of leadership fluctuations since Richard Ridinger left the company in early 2019.
https://www.fiercepharma.com/manufacturing/cdmo-siegfried-expands-us-footprint-acquisition-wisconsin-facility
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Sangamo Therapeutics Secures Accelerated Approval Pathway for Gene Therapy in Fabry Disease
Sangamo Therapeutics has announced a major advancement in its gene therapy program for Fabry disease, as the U.S. FDA has provided a clear pathway for Accelerated Approval. This decision could potentially speed up approval timelines by three years, with a Biologics...
[2024/10/18] Gene and Cell Therapy- weekly digest from PackGene
FeaturedNewsArticlesPackGene's NewsletterReceive the latest news and insights to your inbox.About PackGenePackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span...
GSK sues Moderna over mRNA vaccine patents, seeks ‘reasonable royalty’
GSK on Tuesday unveiled a lawsuit filed against Moderna in Delaware federal court, alleging that its patented inventions provide the “foundation” for Moderna’s mRNA vaccine portfolio. GSK said it’s looking to recover “a reasonable royalty” for Moderna’s tens of...
Gene Therapy Automatically Converts Omega-6 to Omega-3 Fatty Acids in the Body
Shriners Children's Develops New Technology to Prevent Childhood Obesity ST. LOUIS, Oct. 16, 2024 /PRNewswire/ -- According to the Centers for Disease Control, nearly 20% of children and teens are considered obese. Research shows it can have a dramatic impact on a...
Related Services
Plasmids GMP Services
AAV GMP Services
